In vivo characterization
of three VS hit compounds. (A) Naïve
C57Bl/6J mice treated with TN-01 (0.5 mg/kg, n =
6 or 5 mg/kg, n = 5) showed significant decreases
in immobility in the tail suspension test compared to saline-treated
mice (n = 6). (p = 0.016; Dunnett’s
test *p < 0.05 compared to saline.) (B) Naïve
mice treated with TN-06 (1 mg/kg, n = 6; 10 mg/kg, n = 7; 20 mg/kg, n = 6) showed a significant
decrease in immobility at the highest dose compared to saline (n = 6). (p = 0.018; Dunnett’s test
*p < 0.05 compared to saline.) (C) Naïve
mice treated with TN-13 (1 mg/kg, n = 6; 10 mg/kg, n = 6; 20 mg/kg, n = 6) showed a significant
decrease in immobility with the two highest doses compared to saline
(n = 6). (p = 0.0064; Dunnett’s
test *p < 0.05, **p < 0.01
compared to saline.) The distance traveled in an open field compared
to saline-treated mice (n = 5) is shown for mice
treated with (D) TN-01 (5 mg/kg, n = 6), (E) TN-06
(20 mg/kg, n = 5), or (F) TN-13 (1 mg/kg, n = 3; 10 mg/kg, n = 3).